Lexeo Therapeutics, Inc. (LXEO) – What Are Researchers Thinking About This Stock?

Shares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO – Get Free Report) have been assigned an average rating of “Buy” from the eight ratings firms that are currently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, five have given a buy rating and two have assigned a strong buy rating to the company. The average 1-year price target among brokers that have covered the stock in the last year is $16.43.

A number of research analysts recently weighed in on LXEO shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Lexeo Therapeutics in a research report on Wednesday, November 11th. Raymond James Financial reissued a “strong-buy” rating on shares of Lexeo Therapeutics in a research report on Monday. Wall Street Zen cut shares of Lexeo Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Saturday. Cantor Fitzgerald restated an “overweight” rating on shares of Lexeo Therapeutics in a research note on Thursday, November 12th. Finally, Leerink Partners restated an “outperform” rating and issued a $15.00 price objective on shares of Lexeo Therapeutics in a report on Wednesday, September 23rd.

Check Out Our Latest Stock Analysis on LXEO

Institutional Trading of Lexeo Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the stock. Lighthouse Investment Partners LLC bought a new stake in Lexeo Therapeutics during the third quarter worth about $39,000. Marshall Wace LLP bought a new position in Lexeo Therapeutics in the third quarter valued at approximately $840,000. Empowered Funds LLC bought a new position in Lexeo Therapeutics in the third quarter valued at approximately $199,000. Aberdeen Group plc grew its stake in Lexeo Therapeutics by 90.5% in the third quarter. Aberdeen Group plc now owns 1,286,077 shares of the company’s stock valued at $4,347,000 after purchasing an additional 610,985 shares in the last quarter. Finally, Signaturefd LLC increased its position in shares of Lexeo Therapeutics by 5,159.1% during the 3rd quarter. Signaturefd LLC now owns 8,362 shares of the company’s stock worth $28,000 after purchasing an additional 8,203 shares during the last quarter. Institutional investors own 60.67% of the company’s stock.

Lexeo Therapeutics Stock Down 11.5%

NASDAQ LXEO opened at $2.86 on Wednesday. Lexeo Therapeutics has a 12-month low of $2.55 and a 12-month high of $10.99. The company has a market capitalization of $234.66 million, a PE ratio of -2.29 and a beta of 1.64. The firm’s 50 day moving average is $3.31 and its 200-day moving average is $4.96.

Lexeo Therapeutics (NASDAQ:LXEO – Get Free Report) last announced its quarterly earnings data on Monday, November 16th. The company reported ($0.43) EPS for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.11). As a group, sell-side analysts expect that Lexeo Therapeutics will post -1.22 EPS for the current year.

Trending Headlines about Lexeo Therapeutics

Investors following LXEO have been watching these headlines:

  • Positive Sentiment: In the HEROIC-PKP2 Phase 1/2 trial, high-dose participants showed an average 80% reduction in non-sustained ventricular tachycardia and a 44% reduction in premature ventricular contractions. The treatment was generally well tolerated across 10 participants; nine had at least 12 months of follow-up. Company announcement
  • Positive Sentiment: Lexeo said the FDA is open to guideline-defined non-sustained ventricular tachycardia as a potential primary surrogate endpoint for accelerated approval. The company plans to begin a pivotal study in late 2027, offering a possible development path, though approval is not assured. Benzinga report
  • Negative Sentiment: Third-quarter adjusted loss was $0.43 per share, wider than analysts’ $0.32-per-share loss estimate. This earnings shortfall may weigh on sentiment, although the clinical update was the larger focus of recent coverage. Earnings report

Lexeo Therapeutics Company Profile

(Get Free Report)

Lexeo Therapeutics, Inc. is a clinical-stage biotechnology company developing gene therapies for inherited cardiovascular and other serious diseases. Its research focuses on using genetic medicines to address conditions caused by specific gene mutations. The company’s investigational programs include LX2006, a gene therapy being studied for Friedreich ataxia cardiomyopathy, and other candidates targeting genetically defined heart diseases. These therapies remain in development and are not established commercial products.

Recommended Stories

Analyst Recommendations for Lexeo Therapeutics (NASDAQ:LXEO)

Receive News & Ratings for Lexeo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexeo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.